

**Biocon Limited**

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : I24234KA1978PLC003417

www.biocon.com

March 19, 2021

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 050 Scrip Symbol- Biocon
--	---

Subject: Intimation for Incorporation of Wholly Owned Subsidiary Company

Dear Sir/ Madam,

With reference to the captioned subject, we would like to inform you that the Company has incorporated a wholly owned subsidiary company "**Biofusion Therapeutics Limited**" on March 18, 2021.

The details as required under SEBI Listing Regulations read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 are as under: -

S. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Biofusion Therapeutics Limited Share Capital (a) Authorised Share Capital: Rs. 15,00,000 /- (b) Paid-up Capital: Rs. 5,00,000/- Turnover: Nil (Yet to commence business operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature	NA



	of interest and details thereof and whether the same is done at "arm's length"	
3	Industry to which the entity being acquired belongs;	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of wholly owned subsidiary company would be in the field of Research and Development and allied services.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	The Corporate Identity Number ('CIN') of the Company is U73100KA2021PLC145487, issued by Ministry of Corporate Affairs, Government of India.
6	Indicative time period for completion of the acquisition;	NA
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs. 5,00,000/- (50,000 equity shares of Rs. 10/- each)
9	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Biofusion Therapeutics Limited is incorporated with Registrar of Companies, Bengaluru, Karnataka, on March 18, 2021 and is yet to commence its business operations.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

For **Biocon Limited**




Mayank Verma

Company Secretary and Compliance Officer